Pharmaceutically Important Pre- and Posttranslational Modifications on Human Serum Albumin
-
- Otagiri Masaki
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University
-
- Chuang Victor Tuan Giam
- Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University School of Pharmacy, Curtin University of Technology
この論文をさがす
説明
Recombinant technology allows engineering and production of proteins with desirable properties. Human serum albumin has been developed with recombinant technology, and thus plays an increasing role as a drug carrier in the clinical setting. Genetic variations usually occur on the surface of the protein, and do not impose significant effects on the conformation of albumin. However, binding of fatty acids by genetic variants is affected according to the location of the mutation. Albumin undergoes three major posttranslational modifications, namely, oxidation, glycation, and S-nitrosylation. This review gives an account of the different posttranslational modifications that should be taken into consideration when designing albumin mutant analogues with desirable pharmaceutical properties.
収録刊行物
-
- Biological & Pharmaceutical Bulletin
-
Biological & Pharmaceutical Bulletin 32 (4), 527-534, 2009
公益社団法人 日本薬学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282679601139840
-
- NII論文ID
- 110007160707
-
- NII書誌ID
- AA10885497
-
- ISSN
- 13475215
- 09186158
-
- NDL書誌ID
- 10194129
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可